Shares of MYnd Analytics (NASDAQ MYND) traded down $0.25 on Tuesday, reaching $2.44. 4,000 shares of the company’s stock traded hands, compared to its average volume of 10,814. MYnd Analytics has a fifty-two week low of $2.22 and a fifty-two week high of $8.25.
In other MYnd Analytics news, Director John Pappajohn purchased 10,000 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was bought at an average cost of $3.44 per share, with a total value of $34,400.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Peter Unanue purchased 15,000 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were acquired at an average cost of $3.65 per share, with a total value of $54,750.00. The disclosure for this purchase can be found here. Company insiders own 17.81% of the company’s stock.
About MYnd Analytics
MYnd Analytics, Inc, formerly CNS Response, Inc, is a predictive analytics company. The Company has developed a decision support tool to help physicians reduce trial and error treatment in mental health, and provide personalized care to patients. The Company provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (PTSD) and other non-psychotic disorders.
Receive News & Ratings for MYnd Analytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYnd Analytics and related companies with MarketBeat.com's FREE daily email newsletter.